Oculis Holding AG
Licaminlimab
dry eye disease
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Licaminlimab in dry eye disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“PREDICT-1 TLR in around year-end 2026”